AYTU BIOPHARMA, INC
Close on Oct 19, 2026
- Market cap
- $37.82M
- P/E (TTM)
- –
- Dividend yield
- –
About Aytu Biopharma
Pharmaceutical Preparations, SIC 2834
Aytu BioPharma, Inc. is a pharmaceutical company that commercializes prescription therapeutics primarily focused on central nervous system disorders. The company operates in a single business segment consisting of prescription medications sold to pharmaceutical wholesalers, distributors, and pharmacies. Its lead commercial product is EXXUA, an extended-release tablet indicated for the treatment of major depressive disorder in adults. The company also markets an attention deficit hyperactivity disorder portfolio comprising Adzenys XR-ODT and Cotempla XR-ODT, along with an authorized generic, as well as a pediatric portfolio featuring Karbinal ER, an extended-release oral suspension for treating allergic conditions.
The company operates predominantly in the United States, deploying an internal commercial organization with approximately 40 sales territories for EXXUA and a network of over 1,000 participating pharmacies through its patient support program. It has also partnered to commercialize its ADHD treatments in Canada. Aytu BioPharma maintains its principal executive office in Denver, Colorado.
Summary of the business section of Aytu Biopharma's latest annual report, written by StockData.
Company profile
Company
- Legal name
- AYTU BIOPHARMA, INC
- Founded
- 2002
- Headquarters
- Denver, CO
- Address
- 7900 E. Union Avenue, Suite 920 80237
- Phone
- (720) 437-6580
- Website
- aytubio.com
- Employees
- 76, Jun 30, 2026
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- June 30
- Auditor
- GRANT THORNTON LLP, Denver, Colorado
Stock & identifiers
- Ticker
- AYTU
- Exchange
- Nasdaq
- IPO date
- Sep 25, 2008
- Shares outstanding
- 11M, Sep 15, 2026
- Public float
- $23.97M, Dec 31, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-20 reverse, Jan 6, 2023; 1-for-20 reverse, Jan 6, 2023; 1-for-10 reverse, Feb 11, 2021; 1-for-10 reverse, Dec 9, 2020; 1-for-20 reverse, Nov 7, 2018; 1-for-20 reverse, Aug 13, 2018; 1-for-20 reverse, Aug 31, 2017; 1-for-20 reverse, Aug 29, 2017; 1-for-12 reverse, Sep 1, 2016; 1-for-12 reverse, Jul 1, 2016; 1-for-5.67 reverse, Sep 28, 2015
- SEC CIK
- 1385818
- CUSIP
- 054754858
- ISIN
- US0547548588
- LEI
- 549300SMWHEALCU7Q019
- EIN
- 47-0883144
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Joshua R. Disbrow | Chief Executive Officer, Director | 237,203 |
| Greg Pyszczymuka | Chief Commercial Officer | 56,102 |
| Jarrett Disbrow | Chief Business Officer | 76,568 |
| Ryan J. Selhorn | Chief Financial Officer | 74,743 |
| Vivian H. Liu | Director | 29,825 |
| Carl Dockery | Director | 31,202 |
| John Donofrio Jr. | Director | 23,762 |
| Abhinav Jain | Director | 29,500 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 | $883.93K | $867.09K | $462.09K | $16 | – |
| FY2024 | $928.22K | $919.18K | $547.69K | $21 | – |
| FY2023 | $708.00K | $391.85K | $505.96K | $12 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of June 30, 2026, we employed 76 employees, of which 75 were full-time employees.”
Corporate history
Events identified from SEC filings